Search Results - "Lucentis" :: UTM Library Massive Scholar Tracking

41

THE ONE-STAGE COMBINED TECHNOLOGY OF TREATMENT RETINOVASCULAR MACULAR EDEMA «MACULAR DOUBLE BLOCK» by M. I. Ismailov, A. M. Agmadov

Published 2015-10-01

“…In patients of the comparative group the VEGF inhibitor ranibizumab (Lucentis) was injected intravitreally in an amount of 0.5mg monthly within 3 months. …”

Get full text

Article

42

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. by Dakin, H, Wordsworth, S, Rogers, C, Abangma, G, Raftery, J, Harding, S, Lotery, A, Downes, S, Chakravarthy, U, Reeves, B

Published 2014

“…<h4>Objective</h4> <p>To assess the incremental cost and costeffectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective.…”

Journal article

43

A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab by Ozge Tatli, Yagmur Oz, Baran Dingiloglu, Duygu Yalcinkaya, Ezgi Basturk, Melis Korkmaz, Latif Akbulut, Derya Hatipoglu, Cansin Kirmacoglu, Buse Akgun, Kubra Turk, Orkun Pinar, Berna Sariyar Akbulut, Zeynep Atabay, Eda Tahir Turanli, Dilek Kazan, Gizem Dinler Doganay

Published 2023-11-01

“…The purified Fab molecule Ranibizumab possessed a high degree of similarity to its originator Lucentis. The developed purification platform highly intensified the process and provided successful clearance of formulated Fab- and process-related impurities (∼98 %) with an overall process recovery of 50 % and, thus, might be a new option for Fab purification for both academic and industrial purposes.…”

Get full text

Article

44

Ações judiciais relacionadas a medicamentos em João Pessoa, PB, Brasil by Larissa Figueiredo Pacheco, Lailla Yasmin Pereira, Gabriel Rodrigues Martins de Freitas, Rênia Glauciene da Silva Sousa, João Marcos de Araujo da Silva, Bruna Carla Cordeiro de Carvalho

Published 2023-07-01

“…Os medicamentos mais judicializados foram: Lucentis® (Ranibizumabe), Clexane® (Enoxaparina Sódica) e Xarelto® (Rivaroxabana), enquanto os mais onerosos foram: Spiranza®(Nusinersena), Imbruvica®(Ibrutinibe) e Ilaris®(Canaquinumabe). …”

Get full text

Article

45

The role of mitochondrial genes on nuclear gene expression in neovascular age related macular degeneration: analysis of nuclear VEGF gene expression after ranibizumab treatment in... by Rodrigo Donato Costa, Farid José Thomaz Neto, M. Tarek Moustafa, Shari R. Atilano, Marilyn Chwa, Javier Cáceres-del-Carpi, Mohamed Hamid Mohamed, M. Cristina Kenney, Baruch D. Kuppermann

Published 2023-07-01

“…The cybrids were treated with Ranibizumab (Lucentis, Genentech, San Francisco, CA), at 4 different concentrations for 24 h, and subsequently the levels of reactive oxygen species (ROS), gene expression for VEGF-A, hypoxia-inducible factor 1-alpha (HIF1-a) and manganese superoxide dismutase (SOD2) were measured. …”

Get full text

Article

46

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence by Chakraborty D, Mondal S, Boral S, Das A, Sinha TK, Majumdar S, Bhattacharya R, Maitra R

Published 2023-04-01

“…Debdulal Chakraborty,1 Soumen Mondal,1 Subhendu Boral,1 Arnab Das,1 Tushar Kanti Sinha,1 Saptorshi Majumdar,1 Ranabir Bhattacharya,2 Ritobroto Maitra3 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of MIS, Disha Eye Hospitals, Kolkata, West Bengal, India; 3Radical Health Tech, New Delhi, IndiaCorrespondence: Debdulal Chakraborty, Department of Vitreoretinal services, Disha Eye Hospitals, Kolkata, West Bengal, India, Tel +91 33 66360000, Email devdc@rediffmail.comPurpose: To analyse outcomes of innovator ranibizumab (IRM) (Lucentis) and biosimilar ranibizumab (BRM) (Razumab) in Indian eyes with neovascular age-related macular degeneration (nAMD).Methods: Retrospective observational study in nAMD patients, who were treated with IRM or BRM (3 loading doses followed by pro re nata (PRN). …”

Get full text

Article

47

A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVA... by Chakravarthy, U, Harding, SP, Rogers, CA, Downes, S, Lotery, AJ, Dakin, HA, Culliford, L, Scott, LJ, Nash, RL, Taylor, J, Muldrew, A, Sahni, J, Wordsworth, S, Raftery, J, Peto, T, Reeves, BC

Published 2015

“…<p><strong>Background</strong> Bevacizumab (Avastin®, Roche), which is used in cancer therapy, is the ‘parent’ molecule from which ranibizumab (Lucentis®, Novartis) was derived for the treatment of neovascular age-related macular degeneration (nAMD). …”

Journal article

48